TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Evoke Pharma ( (EVOK) ) has shared an announcement.
On November 3, 2025, Evoke Pharma entered into a merger agreement with QOL Medical, which will acquire all outstanding shares of Evoke for $11.00 per share in cash, representing a 139.7% premium to the recent Nasdaq closing price. This strategic acquisition, expected to close by the end of 2025, highlights the value of Evoke’s commercial product, GIMOTI, and aligns with QOL Medical’s mission to expand its gastrointestinal care portfolio. The merger will result in Evoke becoming a wholly owned subsidiary of QOL Medical, ceasing its status as a publicly traded company.
Spark’s Take on EVOK Stock
According to Spark, TipRanks’ AI Analyst, EVOK is a Neutral.
Evoke Pharma’s stock score reflects a company facing financial difficulties despite notable revenue growth. The financial performance heavily weighs down the score due to persistent losses and cash flow issues. Technical analysis suggests bearish trends, and the valuation is unattractive with a negative P/E ratio. However, the earnings call provided a positive outlook, highlighting strategic initiatives and growth prospects, partially balancing the overall score.
To see Spark’s full report on EVOK stock, click here.
More about Evoke Pharma
Evoke Pharma, Inc. is a specialty pharmaceutical company focused on developing drugs to treat gastrointestinal (GI) disorders and diseases. The company developed and markets GIMOTI, a nasal spray formulation of metoclopramide, for treating symptoms associated with acute and recurrent diabetic gastroparesis in adults.
Average Trading Volume: 162,694
Technical Sentiment Signal: Sell
Current Market Cap: $7.15M
See more data about EVOK stock on TipRanks’ Stock Analysis page.